TXMD (TherapeuticsMD, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by TXMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-29 | Tommy G Thompson | Director | Buy | — | — |
| 2025-11-05 | Marlan D Walker | Chief Executive Officer | A | — | — |
| 2025-11-05 | Gail K Naughton | Director | A | — | — |
| 2025-11-05 | Cooper C. Collins | Director | A | — | — |
| 2025-11-05 | Tommy G Thompson | Director | A | — | — |
| 2025-04-15 | Tommy G Thompson | Director | Buy | — | — |
| 2025-04-15 | Marlan D Walker | Chief Executive Officer | Buy | — | — |
| 2025-04-10 | Marlan D Walker | Chief Executive Officer | Buy | — | — |
| 2025-02-20 | Marlan D Walker | Chief Executive Officer | M | — | — |
| 2025-02-20 | Tommy G Thompson | Director | M | — | — |
| 2025-02-20 | Cooper C. Collins | Director | M | — | — |
| 2025-02-20 | Gail K Naughton | Director | M | — | — |
| 2024-08-26 | Cooper C. Collins | Director | Buy | — | — |
| 2024-08-23 | Cooper C. Collins | Director | Buy | — | — |
| 2023-12-07 | Marlan D Walker | Chief Executive Officer | MIXED | — | — |
| 2023-11-17 | David Efraim Rosen | 10%+ Owner | A | — | — |
| 2023-08-21 | JOSEPH ZIEGLER | Principal Financial Officer | A | — | — |
| 2023-07-19 | Gail K Naughton | Director | A | — | — |
| 2023-07-19 | Tommy G Thompson | Director | A | — | — |
| 2023-07-19 | Cooper C. Collins | Director | A | — | — |
| 2023-06-29 | Rubric Capital Management LP | Director | A | — | — |
| 2023-05-04 | Marlan D Walker | Chief Executive Officer | MIXED | — | — |
| 2023-04-14 | Michael C Donegan | Prin. Fin. and Acctg. Officer | M | — | — |
| 2023-04-14 | Marlan D Walker | Chief Executive Officer | MIXED | — | — |
| 2023-02-23 | Michael C Donegan | Prin. Fin. and Acctg. Officer | A | — | — |
| 2023-02-23 | Marlan D Walker | Chief Executive Officer | A | — | — |
| 2023-02-22 | David Efraim Rosen | Director | D | — | — |
| 2023-01-30 | Michael C Donegan | Prin. Fin. and Acctg. Officer | MIXED | — | — |
| 2023-01-25 | Michael C Donegan | Prin. Fin. and Acctg. Officer | MIXED | — | — |
| 2023-01-03 | Rubric Capital Management LP | 10%+ Owner | Sell | — | — |
| 2022-12-12 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2022-12-09 | Mark A Glickman | Co-Chief Executive Officer | MIXED | — | — |
| 2022-12-09 | Brian Bernick | Co-Chief Executive Officer | MIXED | — | — |
| 2022-12-09 | Marlan D Walker | General Counsel | MIXED | — | — |
| 2022-12-09 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2022-12-09 | Michael C Donegan | Interim CFO/CAO/VP of Finance | MIXED | — | — |
| 2022-12-08 | Gail K Naughton | Director | Sell | — | — |
| 2022-10-31 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2022-10-03 | Cooper C. Collins | Director | A | — | — |
| 2022-10-03 | Karen Ling | Director | A | — | — |
| 2022-10-03 | Gail K Naughton | Director | A | — | — |
| 2022-10-03 | Tommy G Thompson | Director | A | — | — |
| 2022-10-03 | JULES A. MUSING | Director | A | — | — |
| 2022-10-03 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2022-10-03 | Angus C. Russell | Director | A | — | — |
| 2022-10-03 | PAUL BISARO | Director | A | — | — |
| 2022-08-22 | PAUL BISARO | Director | M | — | — |
| 2022-08-22 | Karen Ling | Director | M | — | — |
| 2022-08-22 | Angus C. Russell | Director | M | — | — |
| 2022-08-22 | Cooper C. Collins | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,946,908 | — |
| — | Director | 2,069,716 | — |
| — | CEO | 399,833 | — |
| — | Secretary/CEO of subsidiary | 107,586 | — |
| — | Chief Executive Officer | 73,639 | — |
| — | Prin. Fin. and Acctg. Officer | 61,853 | — |
| — | Director | 60,516 | — |
| — | Director | 37,491 | — |
| — | Director | 8,826 | — |
| — | Director | 8,500 | — |
| — | Principal Financial Officer | 7,500 | — |
| — | Director | 5,922 | — |
| — | Director | 5,792 | — |
| — | Director | 4,591 | — |
| — | Chief Financial Officer | 4,343 | — |
| — | Co-Chief Executive Officer | 4,252 | — |
| — | Director | 4,022 | — |
| — | Director | 2,137 | — |
| — | Chief Strategy Officer | 2,114 | — |
| — | EVP, Operations | 2,070 | — |
| — | Co-Chief Executive Officer | 1,734 | — |
| — | Chief Financial Officer | 800 | — |
| — | Director | 63 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TXMD quote page; the site-wide leaderboard is on the insider transactions hub.